Literatur
- 1
Hubert H B, Feinleib M, McNamara P M, Castelli W P.
Obesity as an independent risk factor for cardiovascular disease:a 26-year follow-up
of participants in the Framingham Heart Study.
Circulation.
1983;
67
968-977
- 2
Manson J E, Colditz G A, Stampfer M J, Willett W C, Rosner B, Monson R R. et al .
A prospective study of obesity and risk of coronary heart disease in women.
N Engl J Med.
1990;
322
882-889
- 3
Wilson P W.
Established risk factors and coronary artery disease:the Framingham Study.
Am J Hypertens.
1994;
7(7 Pt 2)
7S-12S
- 4
Rosengren A, Wedel H, Wilhelmsen L.
Body weight and weight gain during adult life in men in relation to coronary heart
disease and mortality. A prospective population study.
Eur Heart J.
1999;
20
269-277
- 5
Hansson G K.
Inflammation, atherosclerosis, and coronary artery disease.
N Engl J Med.
2005;
352
1685-1695
- 6
Shah P K.
Plaque disruption and thrombosis:potential role of inflammation and infection.
Cardiol Rev.
2000;
8
31-39
- 7
Pickup J C.
Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes.
Diabetes Care.
2004;
27
813-823
- 8
Will B, Zeeb H, Baune B T.
Overweight and obesity at school entry among migrant and German children:a cross-sectional
study.
BMC Public Health.
2005;
5
45
- 9
Dietz W H.
Health consequences of obesity in youth:childhood predictors of adult disease.
Pediatrics.
1998;
101(3 Pt 2)
518-525
- 10
Hotamisligil G S, Shargill N S, Spiegelman B M.
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin
resistance.
Science.
1993;
259
87-91
- 11
Stangl K, Cascorbi I, Laule M, Stangl V, Vogt M, Ziemer S. et al .
Elevated serum leptin in patients with coronary artery disease:no association with
the Trp64Arg polymorphism of the beta3-adrenergic receptor.
Int J Obes Relat Metab Disord.
2000;
24
369-375
- 12
Hauner H.
Secretory factors from human adipose tissue and their functional role.
Proc Nutr Soc.
2005;
64
163-169
- 13
Koenig W.
Predicting risk and treatment benefit in atherosclerosis:the role of C-reactive protein.
Int J Cardiol.
2005;
98
199-206
- 14
Ford E S.
C-reactive protein concentration and cardiovascular disease risk factors in children:findings
from the National Health and Nutrition Examination Survey 1999 - 2000.
Circulation.
2003;
108
1053-1058
- 15
Fried S K, Bunkin D A, Greenberg A S.
Omental and subcutaneous adipose tissues of obese subjects release interleukin-6:depot
difference and regulation by glucocorticoid.
J Clin Endocrinol Metab.
1998;
83
847-850
- 16
Festa A, D'Agostino R Jr, Tracy R P, Haffner S M.
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict
the development of type 2 diabetes:the insulin resistance atherosclerosis study.
Diabetes.
2002;
51
1131-1137
- 17
Freeman D J, Norrie J, Caslake M J, Gaw A, Ford I, Lowe G D. et al .
C-reactive protein is an independent predictor of risk for the development of diabetes
in the West of Scotland Coronary Prevention Study.
Diabetes.
2002;
51
1596-1600
- 18
Pradhan A D, Manson J E, Rifai N, Buring J E, Ridker P M.
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.
JAMA.
2001;
286
327-334
- 19
Verma S, Wang C H, Li S H, Dumont A S, Fedak P W, Badiwala M V. et al .
A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production
and inhibits angiogenesis.
Circulation.
2002;
106
913-919
- 20
Verma S, Wang C H, Weisel R D, Badiwala M V, Li S H, Fedak P W. et al .
Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal
with rosiglitazone.
J Mol Cell Cardiol.
2003;
35
417-419
- 21
Blake G J, Ridker P M.
Inflammatory bio-markers and cardiovascular risk prediction.
J Intern Med.
2002;
252
283-294
- 22
Ridker P M, Buring J E, Shih J, Matias M, Hennekens C H.
Prospective study of C-reactive protein and the risk of future cardiovascular events
among apparently healthy women.
Circulation.
1998;
98
731-733
- 23
Larsson P T, Hallerstam S, Rosfors S, Wallen N H.
Circulating markers of inflammation are related to carotid artery atherosclerosis.
Int Angiol.
2005;
24
43-51
- 24
Skurk T, Lee Y M, Hauner H.
Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes
in primary culture.
Hypertension.
2001;
37
1336-1340
- 25
Loskutoff D J, Samad F.
The adipocyte and hemostatic balance in obesity:studies of PAI-1.
Arterioscler Thromb Vasc Biol.
1998;
18
1-6
- 26
Gottschling-Zeller H, Rohrig K, Hauner H.
Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in
cultured human adipocytes.
Diabetologia.
2000;
43
377-383
- 27
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley R E. et al .
Hypoadiponectinemia in obesity and type 2 diabetes:close association with insulin
resistance and hyperinsulinemia.
J Clin Endocrinol Metab.
2001;
86
1930-1935
- 28
Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M. et al .
Reciprocal association of C-reactive protein with adiponectin in blood stream and
adipose tissue.
Circulation.
2003;
107
671-674
- 29
Mannami T, Konishi M, Baba S, Nishi N, Terao A.
Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution
ultrasonography and its relation to cardiovascular risk factors in the general population
of a Japanese city: the Suita study.
Stroke.
1997;
28
518-525
- 30
O"Leary D H, Polak J F, Kronmal R A, Manolio T A, Burke G L, Wolfson S K Jr.
Carotid-artery intima and media thickness as a risk factor for myocardial infarction
and stroke in older adults. Cardiovascular Health Study Collaborative Research Group.
N Engl J Med.
1999;
340
14-22
- 31
Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H. et al .
Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling
through a cAMP-dependent pathway.
Circulation.
2000;
102
1296-1301
- 32
Yang W S, Lee W J, Funahashi T, Tanaka S, Matsuzawa Y, Chao C L. et al .
Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein,
adiponectin.
J Clin Endocrinol Metab.
2001;
86
3815-3819
- 33
Yu J G, Javorschi S, Hevener A L, Kruszynska Y T, Norman R A, Sinha M. et al .
The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and
type 2 diabetic subjects.
Diabetes.
2002;
51
2968-2974
- 34
Christiansen T, Richelsen B, Bruun J M.
Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated
with adiposity and reduced after weight loss in morbid obese subjects.
Int J Obes Relat Metab Disord.
2005;
29
146-150
Dr. med. Thomas Skurk
Else Kröner-Fresenius-Zentrum für Ernährungsmedizin · Technische Universität München
Am Forum 5 · 85350 Freising/Weihenstephan
eMail: ernaehrungsmedizin@wzw.tum.de
